Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion type Assertion NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_head.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion description "[To determine the durability of complete responses in patients with metastatic melanoma or renal cancer treated with high-dose bolus interleukin-2 (IL-2) as well as the factors associated with the development of a complete response and the antigens mediating clinical responses.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion evidence source_evidence_literature NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion SIO_000772 9742914 NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion wasDerivedFrom befree-2016 NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.
- NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_assertion wasGeneratedBy ECO_0000203 NP1404175.RAiR99bnDRA6W9fSbY_OJeTVb-hIEthDKj2kt3opXL4rw130_provenance.